Merck ADC, in China study, shows potential to replace chemo in lung cancer

AI Summary

Merck's antibody-drug conjugate (ADC) showed promising potential in a Chinese study to replace chemotherapy for lung cancer. Wall Street analysts viewed the results as proof-of-concept that the drug could become a future treatment standard.

The results were seen by Wall Street analysts as “direct proof-of-concept” that sac-TMT, a drug Merck views as a “cornerstone,” could be part of a future treatment standard for front-line lung cancer.